DSIP vs Pinealon
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
DSIP
DSIP (Delta Sleep Inducing Peptide) is a nonapeptide (9 amino acids) first isolated from rabbit thalamus in 1974, initially believed to directly induce slow-wave (delta) sleep. Research has since broadened its profile considerably: it modulates the HPA axis (reducing stress-driven cortisol), influences GH and LH release, demonstrates antioxidant properties, and may have cardioprotective effects. Despite decades of research, its precise receptor system remains incompletely characterized.
Full profilePinealon
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology — the same institution behind Epithalon and Cortexin. It is a short peptide bioregulator targeting the pineal gland and central nervous system. Research suggests it acts as an epigenetic regulator, penetrating cell nuclei to modulate gene expression in neurons, with reported effects on sleep quality, neuroprotection, circadian rhythm regulation, and age-related cognitive decline.
Full profile| DSIP | Pinealon | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | Delta Sleep Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu | EDR, Glu-Asp-Arg, Pineal tripeptide |
| Evidence | Research-stage | Research-stage |
| Dosing range | 100mcg–500mcg mcg, Once daily (evening) or every other day | 100mcg–300mcg mcg, Once daily (evening, given melatonin/sleep effects) |
| Administration | Subcutaneous injection, Intranasal, Intravenous (clinical studies) | Subcutaneous injection, Intranasal, Oral (sublingual for better absorption) |
| Key side effects | Generally well-tolerated, Daytime drowsiness if dosed in morning, Mild headache, Altered dream quality (common) | Generally well-tolerated, Drowsiness if dosed during the day, Vivid dreams (common — melatonin pathway activation), Mild headache (uncommon) |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: DSIP — Subcutaneous injection, Intranasal, Intravenous (clinical studies); Pinealon — Subcutaneous injection, Intranasal, Oral (sublingual for better absorption).
- Frequency: DSIP is typically Once daily (evening) or every other day; Pinealon is Once daily (evening, given melatonin/sleep effects).
- Research depth: this profile cites 3 sources for DSIP vs 2 for Pinealon.
How each works
DSIP
DSIP does not directly trigger sleep in the simple sense originally proposed — more recent research indicates it modulates the neuroendocrine environment that facilitates sleep. Key findings: it reduces ACTH-driven cortisol elevation under stress, increases GH secretion in some models, and attenuates withdrawal severity in opioid and alcohol dependence (mechanisms unclear). DSIP demonstrates antioxidant effects and has cardioprotective properties in ischemic preconditioning models in animals. Its unique resistance to most peptidases (attributed to its unusual conformation) gives it a relatively long half-life for a nonapeptide.
Pinealon
Like other peptide bioregulators from the Khavinson group, Pinealon is proposed to work by penetrating the nuclear membrane and interacting directly with histones and promoter regions to regulate transcription. In vitro studies show Pinealon increases synthesis of serotonin and melatonin precursors in pinealocytes and upregulates antioxidant enzyme expression in neuronal cells. Animal studies demonstrate reduced neuronal apoptosis after hypoxic stress and improved performance in cognitive tasks. Clinical observations from Russian gerontology practice suggest benefits for insomnia, age-related cognitive decline, and neurological recovery.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.